Novartis Investor Presentation

New Novartis: Our strategy Our focus Our priorities Abbreviations Conclusion 1L 2/3L First-line IM Innovative Medicines Second or third line LDLC adj.BC Adjuvant breast cancer LMICS Low-density lipoprotein cholesterol Low/middle income countries > Abbreviations aHUS atypical Hemolytic Uremic Syndrome LN Lupus nephritis ALS Amyotrophic lateral sclerosis LP Lichen Planus AML Acute myeloid leukemia Lp(a) AMR axSPA Axial spondyloarthritis BAFF BCR BTK C3G Antimicrobial resistance B-cell activating factor Biochemical recurrence Bruton tyrosine kinase C3 glomerulopathy MBC mCRPC MDS MDT MHSPC MS CML Chronic myeloid leukemia NME CVRR Cardio-vascular risk reduction NSCLC Secondary prevention of cardiovascular events in CVRR-LDLC OA patients with elevated levels of LDLC PCa CVRR-Lp(a) Secondary prevention of cardiovascular events in PDAC patients with elevated levels of lipoprotein (a) PDL-1 ECN EMB Executive committee of Novartis Emerging Market Brands Programmed death-ligand 1 PNH ES-SCLC Extensive stage small cell lung cancer PPGL FA Food allergy PSA IV PSMA GBM Glioblastoma GCA Giant cell arteritis RLI GEA Gastroesophageal adenocarcinoma RLT GEP-NET Gastroenteropancreatic neuroendocrine tumor Sjs GIST Gastrointestinal stromal tumor SMA-IT GRPR Gastrin-releasing peptide receptor SSA Gx Generics TA HA Health authorities TKI iDFS Invasive Disease-Free Survival TPD IgAN IgA nephropathy TPP Lipoprotein(a) Metastatic breast cancer Metastatic castration-resistant prostate cancer Myelodysplastic syndrome Multi Disciplinary Team Metastatic hormone-sensitive prostate cancer Multiple sclerosis New molecular entity Non-small cell lung cancer Osteoarthritis Prostate cancer Pancreatic ductal adenocarcinoma Paroxysmal nocturnal haemoglobinuria Pheochromocytoma and paragangliomas Psoriatic arthritis Intravenous Prostate-specific membrane antigen Radioligand imaging Radioligand therapy Sjögren's syndrome Spinal muscular atropy-intrathecal SubSaharan Africa Strategy Therapeutic area Tyrosine kinase inhibitor Target product profile 34 Novartis Investor Presentation | September 22, 2022 Targeted protein degradation 1 U | NOVARTIS | Reimagining Medicine

View entire presentation